MIMS summary of semaglutide (Rybelsus), first oral glp-1 agonist launched for type II diabetes

Summary notes safety and efficacy were studied in 8 clinical trials (PIONEER 1 to 8) in patients with disease duration ranging from 3.5 to 15 years (n=8842) in settings ranging from monotherapy through to insulin add-on. PIONEER 6 confirmed CV safety was non-inferior to placebo.


Monthly Index of Medical Specialities